Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
CAMBRIDGE, Mass., Feb. 29, 2016 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that Steven Paul, M.D., president and chief executive officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 8:00 a.m. ET in Boston, MA.
A live audio webcast of the presentation can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Contact: Investor Relations: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
